Drugs / LYG-LIV0001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04496479 | Mar 2022 → Aug 2027 expected | liver failure | LyGenesis, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LYG-LIV0001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04496479 ↗ |
| Modality | Cell therapy | “hepatocyte transplantation into lymph nodes” NCT04496479 ↗ |
| Route | Other | “hepatocyte transplantation into lymph nodes via endoscopic ultrasound” NCT04496479 ↗ |